Potential therapeutic role of microRNAs in ischemic heart disease  by Caroli, Annalisa et al.
RP
A
I
a
A
R
R
A
A
K
m
A
M
I
T
C
I
n
e
t
a
t
m
G
0
hJournal of Cardiology 61 (2013) 315–320
Contents lists available at SciVerse ScienceDirect
Journal  of  Cardiology
jo ur nal home page: www.elsev ier .com/ locate / j j cc
eview
otential  therapeutic  role  of  microRNAs  in  ischemic  heart  disease
nnalisa  Caroli  (MD),  Maria  Teresa  Cardillo  (MD),  Roberto  Galea  (MD),  Luigi  M.  Biasucci  (MD) ∗
nstitute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 20 December 2012
eceived in revised form 16 January 2013
ccepted 23 January 2013
vailable online 13 March 2013
eywords:
a  b  s  t  r  a  c  t
Cardiovascular  disease  (CVD)  is  the  most  important  cause  of  death  and  illness  in the  western  world.
Atherosclerosis  constitutes  the single  most  important  contributor  to CVD.
miRNAs  are  small  ribonucleic  acids  (RNAs)  that negatively  regulate  gene  expression  on  the  post-
transcriptional  level  by  inhibiting  mRNA  translation  or promoting  mRNA  degradation.
Several  studies  demonstrated  that  miRNAs  dysregulation  have  a key  role in  the  disease  process  and,  focus-
ing on  atherosclerotic  disease,  in  every  step  of plaque  formation  and  destabilization.  These  data  suggestiRNA
ntimiR
imics
schemic heart disease
herapeutic application
a  possible  therapeutic  application  of  miRNA  modulation,  in particular  dysregulated  miRNAs  can  be mod-
ulated  in disease  process  antagonizing  miRNAs  up-regulated  and  increasing  miRNAs  down-regulated.  In
this  review  we  summarize  the  miRNA  therapeutic  techniques  (antimiR,  mimics,  sponges,  masking,  and
erasers)  underlining  their  therapeutic  advantages  and  evaluating  their  risks  and  challenges.  In  particular,
the use of  miRNA  modulators  as a therapeutic  approach  opens  a novel  and  fascinating  area  of  intervention
in  the  therapy  of ischemic  heart  disease.© 2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
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ntroduction
MicroRNAs (miRNAs) are small (approximately 22 nucleotides)
on-coding ribonucleic acids (RNAs) that negatively regulate gene
xpression at the post-transcriptional level by inhibiting mRNA
ranslation or promoting mRNA degradation [1]. It is estimated that
The biogenesis of the miRNAs is a complex process that involves
two different RNAse III endonucleases, Dicer and Drosha, and con-
sists of two  steps, one in the nucleus and one in the cytoplasm.
In the nucleus, Drosha processes the primiRNAs, the precursor
molecule of the miRNAs, in the premiRNAs that, through exportinbout one-third of genes are regulated by miRNAs. Each miRNA can
arget several mRNAs and each mRNA can be the target of different
iRNAs.
∗ Corresponding author at: Istituto di Cardiologia – Policlinico A Gemelli, L.go
emelli, 8, 00168 Roma, Italy. Tel.: +39 0630154187; fax: +39 063055535.
E-mail address: lmbiasucci@virgilio.it (L.M. Biasucci).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.01.0125, is exported from the nucleus to the cytoplasm. In the cyto-
plasm, Dicer cleaves the premiRNAs into the mature miRNAs. This
ﬁnal product is incorporated as single-stranded RNA into the RNA-
induced silencing complex (RISC) that allows the binding of miRNA
to target mRNA leading to the inhibition of mRNA translation or to
mRNA degradation [2].
Furthermore, recent studies demonstrated that circulating miR-
NAs are carried by exosomes [3] or microparticles (MP) [4]
vier Ltd. All rights reserved.
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evealing a new mechanism of exchange of genetic information
etween cells.
Many miRNAs have a tissue-speciﬁc distribution and play
 key role in physiological conditions. Speciﬁc miRNAs have a
ey role in various biological processes: control of metabolism,
ell-differentiation, cell-proliferation and apoptosis, so they are
nvolved in cardiogenesis, stem cell differentiation, neurogene-
is, hematopoiesis, insulin and other hormones secretion, and
mmune response [5–8]. But miRNAs are also involved in patho-
ogical conditions; dysregulation of speciﬁc miRNAs could take
art in disease development and progression. miRNAs have been
mplicated in cardiovascular disease (CVD), viral infections, neu-
ological and muscular disorders, and in the progression of
ancer [9–12].
Among CVD, there is evidence of miRNA dysregulation in
yocardial infarction (MI) [13,14], cardiac hypertrophy [15], con-
estive heart failure (CHF) [16,17], acute hind-limb ischemia, but
lso in cardiac development, with defects that can cause embryonic
ethality [18].
iRNAs in ischemic heart disease
CVD is the most important cause of death and illness in the
estern world. Atherosclerosis, characterized by the accumula-
ion of lipids and ﬁbrous elements in the arteries, constitutes the
ingle most important contributor to CVD. It is a chronic inﬂam-
atory disease characterized by atherosclerotic plaque formation.
laque formation is a long-standing process, initiating with lipids
nd leukocyte inﬁltration and leading, after the early formation of
atty streak, to a positive remodeling of the artery that tends to
ilate in order to accommodate the growing plaque. Major actors
n this process are vascular endothelial cells, smooth muscle cells,
nd circulating inﬂammatory cells [19]. Endothelial dysfunction is
he ﬁrst step in plaque development. Activated endothelial cells
llow leukocyte and monocyte inﬁltration into the vessel wall. The
onsequential steps are: foam cell formation, plaque angiogene-
is, migration and proliferation of vascular smooth muscle cells
VSMC), ﬁbrous cap destabilization and plaque rupture, and even-
ually, thrombus formation on destabilized plaque leads to acute
oronary syndromes (ACS). In this scenario miRNAs are involved in
ll steps [20–22] (Table 1).
Shear stress induces expression of miR-21 in the endothelial
ells; this miRNA inﬂuences endothelium by decreasing apoptosis
nd activating the nitric oxide (NO) pathway [23] and may  exert an
therosclerosis-protective role. Apoptosis is also reported to play
n important role in progression of left ventricular (LV) remodeling
able 1
ole of miRNAs in atherosclerotic plaque development.
Steps of plaque development miRNA Speciﬁc
Endothelial cells activation miR-21 Decreas
Monocyte activation and
macrophage maturation
miR-155 Mediat
miR-124 Mediat
miR-146 Reduce
macrop
Cholesterol biosynthesis miR-122 Raises L
miR-33 Reduce
Plaque angiogenesis
miR-126 Enhanc
miR-92a Modula
miR-27 Modula
metabo
Fibrous cap stabilization and VSMC proliferation
miR-221/222 Induce 
miR-143/145 Stabiliz
miR-195 Reduce
iRNA, microRNA; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VSMC, vology 61 (2013) 315–320
after acute MI  [24]. So miR-21 could play a fundamental role also
in this phase as it is up-regulated in cardiac ﬁbroblast and its up-
regulation is related to the post-MI remodeling [25].
Leukocyte adhesion is regulated by miR-126: its down-
regulation is related to the up-regulation of vascular cell adhesion
molecule-1 (VCAM-1) enhancing leukocyte adhesion to endothe-
lium [26].
In the development of atherosclerotic plaque and in its desta-
bilization, inﬂammation has a key role [27]; macrophages are the
principle effector cells in the atherosclerotic process.
Several miRNAs are involved in the inﬂammatory macrophage
response such as miR-21, miR-210, miR-146a, miR-34a, miR-147,
and miR-125a-5p, which are up-regulated in atherosclerotic plaque
[28]. In particular miR-155 is speciﬁcally expressed in atheroscle-
rotic plaque and in pro-inﬂammatory macrophages; a recent study
demonstrated that the deﬁciency of miR-155 reduces advanced
atherosclerotic plaque formation by up-regulating Bcl6, which
decreased the expression of chemokine (C–C motif) ligand 2 (CCL2)
in macrophages [29].
Also miR-124 is involved in monocyte maturation, in particu-
lar it degrades CCAAT/enhancer binding protein (C/EBP)  and its
downstream target PU.1 involved in monopoiesis [30].
Another miRNA involved in the inﬂammatory process is miR-
146 that targets tumor necrosis factor (TNF) receptor-associated
factor (TRAF) 6, interleukin-1 receptor-associated kinase (IRAK)
1, signal transducers and activators of transcription (STAT) 1,
interferon regulatory factor (IRF) 5, therefore reducing pro-
inﬂammatory signaling and cytokine expression by macrophages
[31]. Furthermore, miR-146 may  prevent activation of the
CD40/CD40L axis and downstream pro-atherogenic cytokine pro-
duction in macrophages [32].
VSMC are other actors in the atherosclerotic process; their
balance between differentiation and proliferation differentiate a
stable from an unstable plaque. miR-145 and miR-143 have an
important role in the regulation of VSMC phenotype; they move
the balance in favor of a condition that stabilizes the plaque
[33]. Also miR221/222 induce VSMC proliferation [34], while
miR-195 negatively modulates VSMC proliferation and migration
[35].
High levels of low-density lipoprotein (LDL) and low lev-
els of high-density lipoprotein (HDL) are established risk factors
for atherosclerosis. Interestingly, miR-122 participates in the
regulation of cholesterol biosynthetic pathway in particular down-
regulating the 3-hydroxy-3-methylglutayl-CoA-reductase [36],
and miR-33 reduces HDL formation, targeting ATP-binding cassette
transporter (ABCA)-1 [37].
 role of miRNA Reference
es apoptosis of endothelial cells [23]
es inﬂammatory macrophage response [29]
es monocyte maturation [30]
s pro-inﬂammatory signaling and cytokines expression by
hage
[31]
DL levels [36]
s HDL levels [37]
es leukocyte adhesion to endothelium [27]
tes plaque angiogenesis [38]
tes plaque angiogenesis, adipogenesis, inﬂammation, lipid
lism, oxidative stress, insulin resistance and type 2 diabetes
[39]
VSMC proliferation [34]
e the plaque [33]
s VSMC proliferation [35]
ascular smooth muscle cells.
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miR-92a has been associated with plaque angiogenesis, which
s negatively regulated by this miRNA [38]; also miR-27 has been
mplicated in angiogenesis and in other steps of plaque formation,
uch as adipogenesis, inﬂammation, lipid metabolism, oxidative
tress, insulin resistance, and type 2 diabetes, representing a
otential disease biomarker and a novel therapeutic target in
therosclerosis [39].
Several studies have demonstrated dysregulation of miRNA pat-
erns in atherosclerotic vessels compared with healthy control
rteries.
Raitoharju et al. [28] demonstrated that miR-21, miR-210,
iR-146a, miR-34a, iR-147, and miR-125a-5p are up-regulated
n the atherosclerotic plaque compared with non-atherosclerotic
eft internal thoracic arteries. Fichtlscherer et al. evaluated the
iRNA expression of 8 healthy volunteers and 8 patients with
table coronary artery disease (CAD). Interestingly, vascular and
eukocyte-derived miRNA, in particular the angiogenesis-related
iRNAs, such as miR-126 and miR-92a, the inﬂammation asso-
iated miR-155, VSMC-enriched miRNAs, such as miR145 and
iR-17, are signiﬁcantly reduced in patients with CAD, whereas
ardiac miR-133a, miR-208 were slightly increased [40]. The mean-
ng of this different expression is unclear; a possible explanation for
his reduction might be an uptake of circulating miRNAs into the
therosclerotic lesion.
A recent study compared miRNA levels in aorta with miRNA
evel in the coronary sinus; there was a positive transcoronary gra-
ient for miR-133a and miR-499 in patients with ACS, suggesting
hat these miRNAs are released into the coronary circulation during
yocardial injury. On the contrary, there was a signiﬁcant nega-
ive transcoronary gradient for miR-126 suggesting either uptake or
egradation of this miRNA during the passage through the coronary
irculation [41].
iRNA in therapy
The most important implication of these studies is the possi-
le therapeutic application of miRNAs that might open a new and
ascinating area in cardiology.
herapeutic advantages of miRNA
A potential therapeutic advantage of miRNAs is that they target
ultiple genes involved in the same pathway process. On the con-
rary, traditional therapies strongly target a single protein, leaving
he others unaffected and potentially able to maintain the patho-
ogical mechanism. Even if the power of inhibition may  not be the
ame as for traditional therapy, the ﬁnal effect of miRNA modula-
ion might result in a more effective therapy [42].
On the other hand, miRNAs have a speciﬁc and deﬁned tar-
et in the pathogenetic mechanism of the disease, resulting in a
igh speciﬁcity of treatment. Other advantages are the long-lasting
ffect and the bioavailability, in fact, miRNA modulators can efﬁ-
iently act in most tissues in vivo.
It is unclear whether traditional drugs can act regulating miR-
As which are dysregulated in disease processes. A recent study
emonstrated that bone marrow mononuclear cell therapy in MI
locked cardiomyocyte apoptosis thanks to a paracrine regula-
ion of miR-34a [43]. Mun˜oz-Pacheco et al. studied ezetimibe, a
ember of a new class of lipid-lowering compounds that
electively inhibit the intestinal absorption of cholesterol, demon-
trating that it inhibits monocyte to macrophage differentiation
hrough down-regulation of the expression of miR-155, miR-222,
iR-424, and miR-503 [44].
Therefore, the use of both therapies, current traditional drugs
nd miRNA-based therapeutics, could improve the therapeutic
ffect.logy 61 (2013) 315–320 317
How to modulate miRNAs
The modulation of miRNAs is based on antisense technology and
gene therapy approaches.
Targeting miRNAs with antimiRNAs can reduce the levels of
pathogenic or aberrantly expressed miRNAs leading to the activa-
tion of gene expression; on the contrary, the use of miRNA mimics
can elevate the level of miRNAs with a beneﬁcial effect leading to
the suppression of gene expression.
AntimiRs
AntimiRNAs (antimiRs) are modiﬁed antisense oligonucleotides
carrying the complementary reverse sequence of a mature miRNA;
antimiR may  reduce the levels of a pathogenic or aberrantly
expressed miRNA [42]. As an miRNA reduces the expression of its
target genes, an antimiR approach results in an increase in expres-
sion. An antimiR can act at different levels of the miRNA biogenesis.
It can interfere with the export of the pre or primiRNA from the
nucleus; it can bind the premiRNA and prevent its processing or
entry into the RISC; and it can bind to the mature miRNA within
the RISC acting as a competitive inhibitor.
A class of antimiR, antagomir, is conjugated to cholesterol to
facilitate cellular uptake.
The silencing of endogenous miRNA with antagomir has been
studied in vivo, for the ﬁrst time, by Krützfeldt et al. [36]. These
authors used an antagomir to inhibit miR-122, a liver speciﬁc
miRNA implicated in cholesterol and lipid metabolism and in hep-
atitis C virus (HCV) replication obtaining a signiﬁcant reduction in
cholesterol levels in mice [45].
Another study demonstrated that mice treated with antimiR-
33, another miRNA involved in lipid metabolism, showed increased
HDL levels and a consequent regression of atherosclerosis [46]. This
type of treatment combined with statins, raising HDL and lowering
LDL levels, could represent a useful therapeutic strategy [47].
Other studies explored the possible use of antagomir as poten-
tial therapy. Bonauer et al. investigated, in a mouse model of acute
MI,  the effect of the antagomir-92a demonstrating that it may
increase blood vessel growth and improve recovery of damaged
tissue [38].
Other approaches use antimiRs with the locked nucleic acids
(LNA) phosphorithioate chemistry.
These antimiRs are chemically modiﬁed to ensure in vivo stabil-
ity, speciﬁcity, and high binding afﬁnity to the miRNA of interest.
LNA is a nucleic acid modiﬁcation that allows a strong duplex
formation with oligonucleotides enhancing speciﬁcity toward
complementary RNA or DNA [45].
Recent studies showed LNA-modiﬁed oligonucleotide to be efﬁ-
cacious in inducing silencing of cardiac expressed miRNAs and
more potent in inhibiting miRNA function than cholesterol con-
jugated antagomirs [45]. Intravenous injection of LNA-antimiR
resulted in uptake of the LNA-antimiR in cytoplasm of pri-
mate hepatocytes and formation of heteroduplexes between the
LNA-antimiR and miR-122. Efﬁcient silencing of miR-122 was
achieved in primates by three doses of 10 mg/kg LNA-antimiR,
leading to a decrease in total plasma cholesterol that was
dose-dependent, long-lasting, reversible and without any evidence
for LNA-associated toxicities or histopatological changes [45].
Systemic delivery of an antisense oligonucleotide induces
potent and sustained silencing of miR-208a in the heart; ther-
apeutic inhibition of miR-208a by subcutaneous delivery of
antimiR-208a during hypertension-induced CHF, in hypertensive
rats, prevented pathological myosin switching and LV remodeling
improving cardiac function and survival [48].
Hullinger et al. [49] showed up-regulation of miR-15 family
in the ischemic region in mice and pigs. miR-15 was induced
318 A. Caroli et al. / Journal of Cardiology 61 (2013) 315–320
Table  2
Effect of miRNA modulation in cardiovascular disease.
miRNA Target AntimiR/mimics Effects Reference
miR-122 3-Hydroxy-3-methylglutayl-CoA-
reductase
(HMGCR)
Antagomir, LNA-antimiR Reduce plasma cholesterol levels [35,45]
miR-33 ABCA1 AntimiR Increased HDL levels [46]
miR-208 THRAP1 LNA-antimiR Prevents cardiac remodeling [48]
miR-92a ITGA5 Antagomir Enhanced blood vessel growth post-AMI [38]
miR-15 Bcl2, Arl2 LNA-antimiR
Reduce infarct size
[49]Inhibits cardiac remodeling
Enhances cardiac function in response to
ischemic damage
miR-101 cFOS Mimics Antiﬁbrotic action [51]
miR-133 RhoA, Cdc42, Nelf-A7WHSC2 Sponge Exaggerated hypertrophic response [53]
miR-599 Increase cardiomyocyte proliferation
ics
Reduce infarct size
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iRNA, microRNA; LNA, locked nucleic acids; HDL, high-density lipoprotein; AMI, a
n cardiomyocytes under hypoxia conditions and also by subse-
uent reoxygenation. Interestingly, miR-15 inhibition with an
NA-mediated antimiR chemistry in mice reduced infarct size,
nhibiting cardiac remodeling and enhancing cardiac function in
esponse to ischemic damage. Hemodynamic analysis 24 h after
schemia showed a lower LV end-diastolic pressure after infarction
ompared with controls. Also echocardiography, 2 weeks after
schemic injury, showed that the antimiR treatment resulted in
igniﬁcant improvement in ejection fraction, which corresponded
ith a decrease in both end-systolic and end-diastolic LV volumes
Table 2).
iR  mimics
When a disease process is caused by a down-regulation of
iRNAs, the therapeutic approach is to increase miRNA levels
hrough a mimic  approach. Mimics are double-stranded oligonu-
leotides composed by 1 strand, identical to the mature miRNA
guide strand), complexed with a complementary, or partially com-
lementary, strand (passenger strand). Loaded into the RISC, the
uide strand can act as the endogenous miRNA of interest and block
argeted gene expression [50].
To improve stability and cellular uptake miRNA mimics are
hemically modiﬁed into a lipid-based formulation but this formu-
ation may  increase also the cellular uptake in tissue outside of the
arget organ or cell type of interest.
An example of the efﬁcient use of miRNA mimics carried by
denovirus is the in vivo study of Pan et al. [51] that evaluated
he relation between miR-101 and cardiac ﬁbroblast proliferation
n infarcted heart. After coronary artery ligation, the expression
f miR-101 was decreased and ﬁbrosis increased. The anti-ﬁbrotic
ction of miR-101 is mediated by the suppression of cFOS and its
ownstream protein TGF. Moreover in this study, using a miRNA
01 mimic  it was observed that overexpression of miR-101 reduced
eterioration of LV performance, as indicated by the increased ejec-
ion fraction and fractional shortening, an alleviated endothelial
xtracellular matrix deposition, producing an antiﬁbrotic action. In
ddition, miR-101 overexpression reduced apoptosis of cardiomy-
cytes in the peri-infarct area of MI  hearts and it is not a direct effect
ut a consequence of the improved cardiac function by miR-101.
More recently Eulalio et al. ﬁrst demonstrated the possibility of
nducing cardiac regeneration through miRNA mimics. The adult
ardiomyocytes have a limited proliferative capacity, that do not
llow an effective myocardial regeneration after MI.  The treatment
ith miR-590 and miR-199a determined a re-entry of cardiomy-
cytes into cell cycle, leading to the proliferation of differentiated[52]
Improve cardiac function
yocardial infarction.
cardiomyocytes. In particular, the authors delivered these miR-
NAs directly into the heart using an adeno-associated virus vector
and demonstrated that the expression of miR-590 and miR-199a
reduces infarct size and improves cardiac function [52] (Table 2).
Sponges, masking, and erasers
In addition to antimiR and miR  mimics there are other interest-
ing “technical” approaches that can inhibit miRNA expression and
consequentially therapeutically interfere with the disease process.
They are sponges, masking, and erasers.
Therapeutic modulation of miRNA could be established by pre-
venting the miRNA action by “adsorbing” the miRNA [42].
The use of sponge technique allows the prevention of binding
of the miRNA with its mRNA target. In particular a vector harbor-
ing miRNA target sites bind the miRNA and thereby miRNAs do not
bind their mRNA target [53]. The sponge can bind the miRNA with
perfect or imperfect complementarity; the miRNAs remain bound
longer to the imperfect target sites so the function of the miRNA is
better inhibited with imperfect binding sites. Furthermore, sponges
are not speciﬁc to an miRNA, but they are able to block a whole fam-
ily of related miRNAs that have the same target sites. Ebert et al.
reported the reduction of miRNA levels with the use of the sponge
technique [53]. Moreover, Carè et al. ﬁrst demonstrated the silenc-
ing of miR-133 with the overexpression of miRNA binding sites [15]
(Table 2).
Another approach is the use of target masking using oligonu-
cleotides with perfect complementarity with the miRNA target
[54,55]. An advantage of this approach is its speciﬁcity, because
it modulates a speciﬁc miRNA target, whereas inhibiting a miRNA
means modulating miRNA multiple targets with the possibility of
off-target effects.
A third approach is the use of erasers. Erasers are oligonu-
cleotides in which tandem repeats of a sequence perfectly comple-
mentary to the target miRNA inhibits endogenous miRNA function.
Both sponges and erasers scavenge the miRNAs preventing the
binding with the mRNA target but whereas erasers use only 2 copies
of the perfectly complementary antisense sequence of the miRNA,
sponges use multiple antisense copies of an miRNA.
Sponges, masking, and erasers are interesting approaches but
there are no in vivo studies that have demonstrated their efﬁcacy.Challenges and risks: delivery, selectivity, and safety
Delivery is an important challenge of miRNA-based therapy:
miRNA modulators must leave the circulatory system to get into the
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arget tissue, enter the cell membrane, and escape from endosomal
esicles into the cytoplasm [54]. Another obstacle in the blood-
tream is the degradation of miRNA therapeutics by phagocytic
mmune cells. And miRNA therapeutics should not be longer than
 nm to cross the capillary endothelium. Without an efﬁcient deliv-
ry mechanism miRNA therapeutics remain in the bloodstream
ntil ﬁltered by the kidneys or degraded by monocytes. One way to
vercome this obstacle and increase the bioavailability of miRNA
odulators is local delivery by direct injection in target tissue,
ut this approach is limited to eye, skin, mucous membranes, and
umors.
Another and consequent challenge is miRNA-based therapy
electivity and safety. Even if certain miRNAs are expressed in
peciﬁc tissue, as miR-208 in the heart and miR-122 in the liver,
any miRNAs are ubiquitously expressed. MiRNA therapeutics
ould act on targets not involved in the disease process giving,
hus, off-target effects. There are two delivery approaches: con-
ugation and formulation [50]. Conjugation strategy provides the
ttachment of targeting molecules such as peptides, antibodies, or
ther bioactive molecules to the oligonucleotide improving miRNA
odulator uptake in the target cell. Alternatively, formulation
pproach provides the package of oligonucleotide into liposomes
r nanoparticles. This approach facilitates the endocytosis of the
iRNA therapeutics. Another approach achieves cellular uptake
y linking the oligonucleotide with cholesterol. The miRNA mod-
lators could be encapsulated into a lipid-based formulation that
nhances cardiac uptake. To date, these delivery technologies have
emonstrated an efﬁcacy in the delivery to the liver. The explana-
ion is the permeability of liver cells to molecules up to 200 nm in
iameter. For this the liver is the most successful organ for deliv-
ring therapeutic miRNAs.
In heart application speciﬁc technologies could be exploited. In
articular, miRNA therapeutics could be delivered during cardiac
atheterization improving cardiac uptake. In the context of treating
ulnerable plaque, a problem could be the penetration of the ﬁbrous
ap and to overcome this problem a target could be macrophages
hat during their activation would release modiﬁed miRNAs [21].
onclusions
To date, many studies demonstrated the key role of the dysreg-
lation of miRNAs in the disease process and their involvement in
VD. Thus, miRNA modulation could represent a new therapeutic
pproach. Therapies addressing miRNA functions are fascinating
nd promising also in ischemic heart disease, but several biological
nd technical problems (delivery, selectively, safety) still exist and
ust be better addressed. Available data are relatively weak but
onsistent and suggest that microRNAs might represent in the near
uture a real revolution in the therapy of ischemic heart disease in
ll its stages.
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